Plasma Biomarker in Amblyopia Patients

Prognostic Value of Plasma Biomarkers Among Patients With Amblyopia

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05705778

Enrollment

600

Registered

2023-01-31

Start date

2022-11-01

Completion date

2027-10-31

Last updated

2023-01-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amblyopia

Keywords

amblyopia, plasma biomarker, prediction, treatment outcome

Brief summary

This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.

Interventions

PROCEDUREstandard amblyopia treatment

amblyopia treatment following international guidelines and genetic tests.

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

3 Years to 12 Years

Healthy volunteers

Yes

Inclusion criteria

* Diagnosed with amblyopia * 3-12 years of age * Able to tolerate amblyopia treatment * Agree to be involved in this study and agree to have a follow up visit every 3 months.

Exclusion criteria

* Have previous treatment history before * Have pathological ocular anomalies known to cause reduced visual acuity * Have previous psychiatric, visual or neurological disorders * Have eccentric fixation and/or abnormal retinal correspondence * Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves

Design outcomes

Primary

Measure	Time frame	Description
Plasma protein predictor screening for visual acuity improvement following amblyopia therapy using Tandem Mass Tags proteomics	2 years after including into this clinical trial	Peripheral blood will be collected prior and after treatment. The plasma will be separated and Tandem Mass Tags will be used for proteomics. We will detect the different expression of plasma protein between successfully treated and untreated amblyopia patients to find biomarkers that predict amblyopia treatment success. Amblyopia treatment success is defined as best corrected visual acuity (BCVA) improvement of 3 or more logMAR lines.

Countries

China

Contacts

Primary ContactJinrong Li, PhD

lijingr3@mail.sysu.edu.cn86-020-87330351

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026